Biosimilar Development News
-
Samsung Bioepis Presents Post-Hoc Analysis Of Phase 3 Study For EPYSQLI (SB12; Eculizumab Biosimilar), At The European Hematology Association (EHA) Congress 2024
6/14/2024
Samsung Bioepis Co., Ltd. today presented the post-hoc analysis of the Phase 3 clinical study results for EPYSQLI (SB12), a biosimilar to Soliris1 (eculizumab), at the 29th European Hematology Association 2024 (EHA2024) Hybrid Congress held in Madrid, Spain and virtually, from June 13 to 16, 2024.
-
B.C.'s Biosimilar Initiative Saves Money, Reinvests To Expand Drug Coverage
6/14/2024
People in B.C. continue to benefit from the Province’s biosimilars initiative as cost savings increase and are reinvested into BC PharmaCare to further improve access to drug coverage.
-
Celltrion Showcases Promising Results In Phase III Study For CT-P47, A Biosimilar Candidate Of RoActemra (tocilizumab) In Patients With Rheumatoid Arthritis (RA) At EULAR 2024
6/13/2024
Celltrion today presented positive Phase III data for CT-P47, a biosimilar candidate referencing RoActemra in patients with moderate-to-severe rheumatoid arthritis (RA), at the Annual European Congress of Rheumatology (EULAR) 2024.
-
Serve You Rx Launches Biosimilar Advantage Formulary To Provide Lower Upfront Cost Options For Specialty Drugs
6/12/2024
Serve You Rx, a full-service pharmacy benefit manager (PBM) known for its unquestionable flexibility and unwavering commitment to doing what's best for its clients, today announced the launch of its new Biosimilar Advantage Formulary.
-
Investment Opportunity: Plantform Corporation Seeks $25M To Accelerate Plant-Based Medical Breakthroughs
6/12/2024
US Capital Global Securities LLC, an SEC-registered affiliate of renowned global financial group US Capital Global, is pleased to present eligible investors with a unique investment opportunity to participate in an investment round of up to $25 million for PlantForm Corporation (“PlantForm” or the “Company”).
-
Alvotech And STADA Add To Strategic Alliance Through Denosumab Partnership
6/11/2024
Alvotech and STADA are strengthening their existing strategic alliance for high-quality, cost-effective biosimilars by extending their partnership to cover AVT03, a clinical-stage biosimilar candidate referencing the Prolia®/Xgeva® (denosumab) medicines for osteoporosis and cancer-related bone loss respectively.
-
New PRI Brief: Biosimilar Competition Lowers Patient Drug Costs, New Competition Will Bring Even More Savings
6/11/2024
A new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute provides the latest evidence that biosimilar competition is saving patients billions -- and additional competition would increase savings even more.
-
Henlius Trastuzumab Begins Its Journey To Saudi Arabia
6/7/2024
On June 6, 2024, Henlius' independently developed and produced product, HANQUYOU (trade name: HERCESSI in the U.S. and Zercepac in Europe), left Henlius’ Xuhui Facility, heading to Saudi Arabia, with the expectation of being the first Chinese monoclonal antibody (mAb) biosimilar to hit the market in the Middle East.
-
Bio-Thera Solutions Receives Positive CHMP Opinion For Avzivi® (bevacizumab), A Biosimilar Referencing Avastin®
6/3/2024
Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion for Avzivi® (bevacizumab), a biosimilar monoclonal antibody referencing AVASTIN®.
-
Samsung Bioepis To Present Post-Hoc Analysis Of Phase 3 Study For EPYSQLI™ (SB12; Eculizumab Biosimilar), At The European Hematology Association (EHA) Congress 2024
5/30/2024
Samsung Bioepis Co., Ltd. today announced that a post-hoc analysis of the Phase 3 clinical study results for EPYSQLI™ (SB12), a biosimilar to Soliris1 (eculizumab), will be presented at the 29th European Hematology Association 2024 (EHA2024) Hybrid Congress held in Madrid, Spain and virtually, from June 13 to 16, 2024.